An interventional study of Standard Environmental Design and Individual Environmental Design in Alzheimer Disease, sponsored by Elizabeth K Rhodus. Completed at 1 site in United States. Open to participants aged 21 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-12.
Sponsored by Elizabeth K Rhodus · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.
Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 1,147th largest by enrollment of the 1,610 interventional ones that give a count, is one of 145 that started in 2021, is one of 610 with no phase, and was the 1,244th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:
National Institute on Aging (NIA) · Sites in United States
Ages 55–110 · Healthy volunteers
National Institute on Aging (NIA) · Sites in United States
Ages 65–120 · Healthy volunteers
Prevention Research Consortium Corp. · Sites in United States
Ages 55+ · Healthy volunteers
Hoffmann-La Roche · Sites in United States, Australia, France and 2 more countries
Ages 50–90
University of Wisconsin, Madison · Sites in United States
Ages 60+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 21 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,941 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 371 · Phase 2 469 · Phase 3 230 · Phase 4 60
First in 1981; this study’s year is marked. 145 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 73 across the 1,610 interventional studies, 160 across the 309 observational. Of the 1,379 that completed or were terminated, 592 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
731 of 1,941 have an industry lead sponsor. The 10 most frequent:
Elizabeth K Rhodus is the lead sponsor of 4 studies on the registry; none are open to participants now.
Elizabeth K Rhodus has 3 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
164 of the studies in Alzheimer Disease with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03860857Phase 3University of California, IrvineBiomarker Exploration in Aging, Cognition and Neurodegeneration | 2026-12-22 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
Add all 164 to your calendar (.ics) → With an account.
Among the 1,941 studies in Alzheimer Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Individuals with dementia present with changes in behaviors throughout the continuum of cognitive decline. Environmental features may be influential in behavioral regulation. The purpose of this study is to assess the feasibility of environmental design protocols in older adults with dementia and their caregivers. Thirty subjects with moderate to severe Alzheimer's disease as primary dementia type, and their caregivers, will be randomly assigned to one of three arms: standard care; standard environmental design protocol; or personalized environmental design protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Alzheimer's disease patients and caregivers.
Behavioral: Placebo
Alzheimer's disease patients and caregivers.
Behavioral: Standard Environmental Design
Alzheimer's disease patients and caregivers.
Behavioral: Individual Environmental Design
Participants' caregivers will receive set script of physical environmental modifications (i.e., declutter living space, reduce background noise, increase natural light), and social environment training script will include caregiving techniques: training for calming demeanor (emotional contagion), needs-driven care to decrease behavioral disruption, and accepting and accommodating approach to behavioral disruption. A pre-selected sensory stimulation kit will be provided to each participants' caregiver for administration throughout the day.
Participants' caregivers will receive set script of physical environmental modifications and social environment training script in a standard protocol. Following initial assessments, individualized sensory stimulation kits will be developed using subjects' preferred sensory stimuli (as determined by the Adult Sensory Profile assessment and informant report) and will be provided via caregiver administration throughout the day to promote maintained behavioral regulation.
Participants' caregivers will receive a set script of placebo modifications.
Success Rate of Adherence
Percentage of participants who had 75% adherence to the protocol based on visits and journals.
Time frame: 6 weeks
Change in Occupational Performance
Occupational performance will be measured using the Canadian Occupational Performance Measure (COPM) at baseline, post-intervention and the 4-week follow up. Scores range from 0-10; higher scores indicate (increased) occupational performance.
Time frame: 10 weeks (at baseline, 6 weeks and the 4 week follow up)
Change in Behavior
Behavior will be measured using the Neuropsychiatric Inventory (NPI-Q) at baseline, post-intervention and the 4-week follow up. Scores range from 1-36; higher scores indicate higher behavior severity.
Time frame: 10 weeks (at baseline, 6 weeks and the 4 week follow up)
Individuals diagnosed with Alzheimer's disease (Clinical Dementia Rating Scale \[CDR\] score of 1.0+) living in the community with caregiver-identified behavioral disturbance were recruited from the UK Alzheimer's Disease Research Center (UK ADRC)
| Milestone | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol |
|---|---|---|---|
| Started | 10 | 10 | 10 |
| Completed | 7 | 9 | 9 |
| Not completed | 3 | 1 | 1 |
| Withdrew: Death | 1 | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 | 0 |
Percentage of participants who had 75% adherence to the protocol based on visits and journals.
| Participants | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol |
|---|---|---|---|
| Success Rate of Adherence | 2 | 6 | 7 |
Occupational performance will be measured using the Canadian Occupational Performance Measure (COPM) at baseline, post-intervention and the 4-week follow up. Scores range from 0-10; higher scores indicate (increased) occupational performance.
| score on a scale | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol |
|---|---|---|---|
| Baseline | 4.6 ± 0.4 | 3.6 ± 0.8 | 4.4 ± 0.8 |
| Post Intervention | 4.6 ± 1.6 | 6.1 ± 1.1 | 6.6 ± 0.9 |
| 4-week follow up | 5 ± 1.4 | 5.2 ± 2.6 | 6.4 ± 2.6 |
Behavior will be measured using the Neuropsychiatric Inventory (NPI-Q) at baseline, post-intervention and the 4-week follow up. Scores range from 1-36; higher scores indicate higher behavior severity.
| score on a scale | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol |
|---|---|---|---|
| Baseline | 13.3 ± 2.3 | 9.8 ± 2.8 | 10.3 ± 1.7 |
| Post-Intervention | 8.9 ± 2.5 | 10.8 ± 1.9 | 8.4 ± 1.7 |
| 4-week follow up | 5.4 ± 2.7 | 5.5 ± 3.0 | 5.8 ± 3.7 |
Collected over 10 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control Group | 1/10 (10%) | 0/10 (0%) | 0/10 (0%) |
| Standard Environmental Design | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Individualized Environmental Design Protocol | 1/10 (10%) | 0/10 (0%) | 0/10 (0%) |
| Age, Continuous(years) | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol | Total |
|---|---|---|---|---|
| PLWD | 77.2 ± 7.4 | 84.3 ± 5.4 | 73.3 ± 7.1 | 77.9 ± 7.9 |
| Caregiver | 69.5 ± 14.0 | 67.7 ± 11.6 | 69.7 ± 11.7 | 69.0 ± 11.7 |
| Sex: Female, Male(Participants) | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol | Total |
|---|---|---|---|---|
| PLWD — Female | 6 | 7 | 8 | 21 |
| PLWD — Male | 4 | 3 | 2 | 9 |
| Caregiver — Female | 9 | 8 | 2 | 19 |
| Caregiver — Male | 1 | 2 | 8 | 11 |
| Race (NIH/OMB)(Participants) | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol | Total |
|---|---|---|---|---|
| PLWD — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| PLWD — Asian | 0 | 0 | 0 | 0 |
| PLWD — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| PLWD — Black or African American | 1 | 0 | 0 | 1 |
| PLWD — White | 9 | 10 | 10 | 29 |
| PLWD — More than one race | 0 | 0 | 0 | 0 |
| PLWD — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Caregiver — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Caregiver — Asian | 0 | 0 | 0 | 0 |
| Caregiver — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Caregiver — Black or African American | 1 | 0 | 0 | 1 |
| Caregiver — White | 9 | 10 | 10 | 29 |
| Caregiver — More than one race | 0 | 0 | 0 | 0 |
| Caregiver — Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol | Total |
|---|---|---|---|---|
| United States | 10 | 10 | 10 | 30 |
| Education(years) | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol | Total |
|---|---|---|---|---|
| PLWD | 14.7 ± 3.2 | 14.6 ± 2.1 | 15.6 ± 2.0 | 15.0 ± 2.4 |
| Caregiver | 15.3 ± 2.5 | 16.3 ± 1.6 | 17.0 ± 2.4 | 16.3 ± 2.2 |
| Length of Caregiving Relationship(years) | Control Group | Standard Environmental Design | Individualized Environmental Design Protocol | Total |
|---|---|---|---|---|
| Mean | 3.7 ± 3.5 | 3.3 ± 2.9 | 5.6 ± 3.9 | 4.4 ± 3.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2021 to primary completion in Oct 2021, 8 months.
Results were first posted in Apr 2023, 1 year 5 months after primary completion.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's 8 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Elizabeth K Rhodus